(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy. VYVDURA is ...

The following is a summary of “Evaluation of myelin content in the spinal cord of patients with multiple sclerosis: a ...

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Demyelinating Diseases.

The study, led by Patrizia Casaccia, founding director of the Advanced Science Research Centre at the CUNY Graduate Centers ...

It is a Christmas miracle in Georgetown! A local business owner gathered friends, family, and community members to help bring ...

Supplements and injections are effective ways to treat vitamin B12 deficiencies. These are the benefits and potential risks ...

All securities issued in the Second Tranche are subject to a statutory hold period of four months and one day from the date of issuance. All amounts in this press release are expressed in Canadian ...

At first, I was skeptical, like many of the people I read about in ProNerve6 reviews. However, after reading through multiple ...

HyQvia was approved by the FDA in January as a maintenance therapy to prevent relapse of neuromuscular disability and ...

Recent research highlights a decline in reading for enjoyment, with significant portions of the population, especially ...